ArticleFrontiers in pharmacology2019
Fusogenic Liposomes Increase the Antimicrobial Activity of Vancomycin Against
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 89 citations in OpenAlex.
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Nanomedicine applications for the treatment of Staphylococcus aureus infections.FEMS microbiology reviews · 2026Review
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
- Liposomal Fluopsin C: Physicochemical Properties, Cytotoxicity, and Antibacterial Activity In Vitro and over In Vivo MDRAntibiotics (Basel, Switzerland) · 2025Article
- Emerging trends of biomedical nanotechnology in nutrition, health monitoring and disease diagnosis.3 Biotech · 2025Review
- The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.Discover nano · 2025Review
- A Comprehensive Analysis of Liposomal-Based Nanocarriers for Treating Skin and Soft Tissue Infection.Current drug delivery · 2025Review
- Fighting fibrin with fibrin: Vancomycin delivery into coagulase-mediated Staphylococcus aureus biofilms via fibrin-based nanoparticle binding.Journal of biomedical materials research. Part A · 2024Article
- Nanomedicines as a cutting-edge solution to combat antimicrobial resistance.RSC advances · 2024Review
- Enhancing Gentamicin Antibacterial Activity by Co-Encapsulation with Thymoquinone in Liposomal Formulation.Pharmaceutics · 2024Article
- Fusogenic Liposomes for the Intracellular Delivery of Phosphocreatine.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Characterization Methods for Nanoparticle-Skin Interactions: An Overview.Life (Basel, Switzerland) · 2024Review
- Liposomal Rifabutin-A Promising Antibiotic Repurposing Strategy against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- Effect of poly (lactic-co-glycolic acid) polymer nanoparticles loaded with vancomycin against Staphylococcus aureus biofilm.BMC biotechnology · 2023Article
- Drug delivery strategies for antibiofilm therapy.Nature reviews. Microbiology · 2023Review
- Controlling the Evolution of Selective Vancomycin Resistance through Successful Ophthalmic Eye-Drop Preparation of Vancomycin-Loaded Nanoliposomes Using the Active-Loading Method.Pharmaceutics · 2023Article
- Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study.Pharmaceutics · 2023Article
- Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation.Antibiotics (Basel, Switzerland) · 2023Review
- Key Design Features of Lipid Nanoparticles and Electrostatic Charge-Based Lipid Nanoparticle Targeting.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.